This is what the news should sound like. The biggest stories of our time, told by the best journalists in the world. Hosted by Michael Barbaro and Sabrina Tavernise. Twenty minutes a day, five days a week, ready by 6 a.m. Unlock full access to New York Times podcasts and explore everything from politics to pop culture. Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. Listen to this podcast in New York Times Audio, our new iOS app for news subscribers. Download now at ...
…
continue reading
Inhoud geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Player FM - Podcast-app
Ga offline met de app Player FM !
Ga offline met de app Player FM !
S6 Ep2: Biosimilars Rheumatology Roundup for January 2023—Podcast Edition
MP3•Thuis aflevering
Manage episode 354512303 series 2161808
Inhoud geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Show notes
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar-
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar-
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis
151 afleveringen
MP3•Thuis aflevering
Manage episode 354512303 series 2161808
Inhoud geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Audioboom and Not So Different: a Podcast from The Center for Biosimilars of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.
Show notes
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar-
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
https://www.centerforbiosimilars.com/view/biosimilars-check-in-approval-in-saudi-arabia-launch-in-republic-of-korea-dr-reddy-s-completes-study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
https://www.centerforbiosimilars.com/view/study-does-adalimumab-lose-effectiveness-after-switching-to-a-biosimilar-
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
https://www.centerforbiosimilars.com/view/case-study-treatment-with-adalimumab-biosimilar-resolved-pediatric-scalp-nail-psoriasis
151 afleveringen
Alle afleveringen
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.